A phase II study of recombinant human granulocyte-colony stimulating factor (rHuG-CSF, lenograstim) in the treatment of agranulocytosis in children.

@article{Donadieu1994API,
  title={A phase II study of recombinant human granulocyte-colony stimulating factor (rHuG-CSF, lenograstim) in the treatment of agranulocytosis in children.},
  author={Jean Donadieu and Patrick Boutard and Gilbert Tchernia and Gerry Oster and Edward C Gordon-Smith and No{\"e}l Philippe and E le Gall and Jean Louis Nivelon and P Dopfer and Annie Babin-Boilletot},
  journal={Nouvelle revue francaise d'hematologie},
  year={1994},
  volume={36 6},
  pages={441-8}
}
The present study evaluated the clinical efficacity and tolerability of the subcutaneous (SC) administration of lenograstim, a glycosylated form of rHuG-CSF identical to human G-CSF, in the treatment of congenital agranulocytosis. Assessment criteria included neutrophil response and response stability, incidence and severity of infection and gingivostomatitis and quality of life. Lenograstim, at induction dosages of 5 (n = 9), 10 (n = 2) or 20 (n = 1) microgram/kg/day SC, produced neutrophil… CONTINUE READING